These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 377468)

  • 21. Infection in burns.
    Settle JA
    J Hosp Infect; 1985 Sep; 6 Suppl B():19-29. PubMed ID: 2865307
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chemotherapy and chemoprophylaxis of burn wound infection (author's transl)].
    Müller FE
    Unfallheilkunde; 1980 Nov; 83(11):530-4. PubMed ID: 7008305
    [No Abstract]   [Full Text] [Related]  

  • 23. The bacteriology of burns.
    Lawrence JC
    J Hosp Infect; 1985 Sep; 6 Suppl B():3-17. PubMed ID: 2865308
    [No Abstract]   [Full Text] [Related]  

  • 24. Infection control in burn patients.
    Heggers JP; Robson MC
    Clin Plast Surg; 1986 Jan; 13(1):39-47. PubMed ID: 3956082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 1% silver sulfadiazine with and without 1% chlorhexidine digluconate for topical antibacterial effect in the burnt infected rat.
    Snelling CF; Roberts FJ
    J Burn Care Rehabil; 1988; 9(1):35-40. PubMed ID: 3128553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro penetration of topical antiseptics through eschar of burn patients.
    Stefanides MM; Copeland CE; Kominos SD; Yee RB
    Ann Surg; 1976 Apr; 183(4):358-64. PubMed ID: 1267492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound.
    Hurtuk MG; He LK; Szilagyi A; Gamelli RL; Hecht DW; Kennedy RH; Rhys-Williams W; Love WG; Shankar R
    J Burn Care Res; 2010; 31(3):462-9. PubMed ID: 20453736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of silver sulphadiazine 1 per cent, silver sulphadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent and mafenide acetate 8.5 per cent for topical antibacterial effect in infected full skin thickness rat burn wounds.
    Gray JH; Henry DA; Forbes M; Germann E; Roberts FJ; Snelling CF
    Burns; 1991 Feb; 17(1):37-40. PubMed ID: 2031672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a new topical agent for burn therapy. Silver sulfadiazine (silvadene).
    Ballin JC
    JAMA; 1974 Nov; 230(8):1184-5. PubMed ID: 4479596
    [No Abstract]   [Full Text] [Related]  

  • 30. The efficacy of nystatin combined with topical microbial agents in the treatment of burn wound sepsis.
    Heggers JP; Robson MC; Herndon DN; Desai MH
    J Burn Care Rehabil; 1989; 10(6):508-11. PubMed ID: 2600098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of a topical antibacterial agent (silver sulfadiazine) on soft-tissue wounds].
    Bocchiotti G; Robotti E
    Minerva Chir; 1990 May; 45(9):677-81. PubMed ID: 2202932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study.
    Ahuja RB; Gupta A; Gur R
    Burns; 2009 Aug; 35(5):672-6. PubMed ID: 19443125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment recommendations for topical burn therapy.
    Monafo WW; West MA
    Drugs; 1990 Sep; 40(3):364-73. PubMed ID: 2226220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteriological cultures on admission of the burn patient: To do or not to do, that's the question.
    Dokter J; Brusselaers N; Hendriks WD; Boxma H
    Burns; 2016 Mar; 42(2):421-7. PubMed ID: 26777453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of invasive Enterobacter cloacae burn wound sepsis with topical nitrofurazone.
    Munster AM
    J Trauma; 1984 Jun; 24(6):524-5. PubMed ID: 6737529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burn wound management.
    Davies MR; Rode H; Cywes S; van der Riet RL
    Prog Pediatr Surg; 1981; 14():33-61. PubMed ID: 7012931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective intestinal decontamination for prevention of wound colonization in severely burned patients: a retrospective analysis.
    Manson WL; Klasen HJ; Sauer EW; Olieman A
    Burns; 1992 Apr; 18(2):98-102. PubMed ID: 1590940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infection by the distribution of biotypes of enterobacteriacease species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe.
    Van der Waaij D; Tielemans-Speltie TM; De Roeck-Houben AM
    Infection; 1977; 5(3):188-94. PubMed ID: 269842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evaluation of nasal mupirocin to prevent Staphylococcus aureus burn wound colonization in routine clinical practice.
    Jaspers ME; Breederveld RS; Tuinebreijer WE; Diederen BM
    Burns; 2014 Dec; 40(8):1570-4. PubMed ID: 24685351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiology of burn wound infections: then and now.
    Mayhall CG
    Clin Infect Dis; 2003 Aug; 37(4):543-50. PubMed ID: 12905139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.